The characteristics of the tumor microenvironment vary widely. New work shows that after tumor-associated expression of the receptor TIM-3 by dendritic cells, TIM-3 inhibits the antitumor efficacy of DNA vaccines and chemotherapy by binding to the damage-associated molecular pattern molecule, HMGB1.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Tim-3 protects against cisplatin nephrotoxicity by inhibiting NF-κB-mediated inflammation
Cell Death Discovery Open Access 01 July 2023
-
Expression changes of Tim-3 as one of supplementary indicators for monitoring prognosis of liver pathological changes in chronic HBV infection
BMC Infectious Diseases Open Access 11 November 2022
-
TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy
Cell Communication and Signaling Open Access 22 February 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Watson, J.D. & Crick, F.H.C. Nature 171, 737–738 (1953).
Chiba, S. et al. Nat. Immunol. 13, 832–842 (2012).
Lotze, M.T. et al. Immunol. Rev. 220, 60–81 (2007).
Ndhlovu, L.C. et al. Blood 119, 3734–3743 (2012).
Semino, C., Angelini, G., Poggi, A. & Rubartelli, A. Blood 106, 609–616 (2005).
Yanai, H. et al. Nature 462, 99–103 (2009).
Dupont, N. et al. EMBO J. 30, 4701–4711 (2011).
Tang, D. et al. J. Cell Biol. 190, 881–892 (2010).
Yang, Z.Z. et al. J. Clin. Invest. 122, 1271–1282 (2012).
Fourcade, J. et al. J. Exp. Med. 207, 2175–2186 (2010).
Tang, D. et al. Oncogene 29, 5299–5310 (2010).
Ben Lu, T.N., Inouye, K., Li, J., Tang, Y. & Lundbäck, P. Nature advance online publication, doi:10.1038/nature11290 (8 July 2012).
Venereau, E. et al. J. Exp. Med. (in the press).
Tang, D., Kang, R., Coyne, C.B., Zeh, H.J. & Lotze, M.T. Immunol. Rev. (in the press).
Weiner, L.M. & Lotze, M.T. N. Engl. J. Med. 366, 1156–1158 (2012).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Tang, D., Lotze, M. Tumor immunity times out: TIM-3 and HMGB1. Nat Immunol 13, 808–810 (2012). https://doi.org/10.1038/ni.2396
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.2396
This article is cited by
-
Tim-3 protects against cisplatin nephrotoxicity by inhibiting NF-κB-mediated inflammation
Cell Death Discovery (2023)
-
Tumor-associated neutrophils upregulate PANoptosis to foster an immunosuppressive microenvironment of non-small cell lung cancer
Cancer Immunology, Immunotherapy (2023)
-
The kinetics of inhibitory immune checkpoints during and post-COVID-19: the knowns and unknowns
Clinical and Experimental Medicine (2023)
-
High-Mobility Group Box 1 in Spinal Cord Injury and Its Potential Role in Brain Functional Remodeling After Spinal Cord Injury
Cellular and Molecular Neurobiology (2023)
-
Expression changes of Tim-3 as one of supplementary indicators for monitoring prognosis of liver pathological changes in chronic HBV infection
BMC Infectious Diseases (2022)
